To validate the biological function of circZFR in vivo, we injected circZFR antisense oligonucleotide (ASO) into the established patient-derived tumor xenograft (PDTX) model and observed that ASO targeting circZFR significantly attenuated tumor growth as well as the inclusion of MYO1B exon 23 (Fig. 6d, f-h). Here, MYO1B is linked to neoplasm.